AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as tyrosine kinase inhibitors) in preclinical tumor models.
Other Research Including AT-101
Ascenta Therapeutics also announced that researchers from the
|SOURCE Ascenta Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved